Przegląd Dermatologiczny

Pełna treść

1/2026 vol. 113
Opis przypadku

Maculopapular Cutaneous Mastocytosis: a Case Report with Particular Emphasis on Management

Anna M. Modzelewska 1
,
Weronika Durańska 1
,
Laura Szajwa 1
,
Wiktoria I. Gula 1
,
Anna Baran 1
,
Iwona Flisiak 1

  1. Department of Dermatology and Venereology, Medical University of Bialystok, Poland

DOI: https://doi.org/10.5114/dr.2026.161418
Data publikacji online: 2026/06/05
Plik artykułu
Maculopapular Cutaneous.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Rudnicka L., Olszewska M., Rakowska A., Sar-Pomian M.: Współczesna dermatologia. PZWL, Warszawa, 2024.
  2. Lange M., Flisiak I., Kapińska-Mrowiecka M.L., Kaszuba A., Maj J., Rudnicka L., et al.: Mastocytoza. rekomendacje diagnostyczno-terapeutyczne Polskiego Towarzystwa Dermatologicznego. Przegl Dermatol 2018, 105, 358-383.
  3. Siebenhaar F., Akin C., Bindslev-Jensen C., Maurer M., Broesby-Olsen S.: Treatment strategies in mastocytosis. Allergy 2014, 34, 433-447.
  4. Hartmann K., Escribano L., Grattan C., Brockow K., Carter M.C., Alvarez-Twose I., et al.: Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis. J Allergy Clin Immunol 2016, 137, 35-45.
  5. Valent P., Akin C., Hartmann K., Alvarez-Twose I., Brockow K., Hermine O., et al.: Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere 2021, 5, e646.
  6. Valent P., Akin C., Sperr W.R., Horny H.P., Arock M., Metcalfe D.D.: New insights into the pathogenesis of mastocytosis: Emerging concepts in diagnosis and therapy. Annu Rev Pathol 2023, 18, 361-386.
  7. Czelej D., Urban J., Wojnowska D., Pietrzak A., Chodorowska G., Wawrzycki B., et al.: Mastocytozy u dzieci i dorosłych – rozpoznawanie i postępowanie. Przegl Dermatol 2006, 93, 83-87.
  8. Sarkany R.P., Monk B.E., Handfield-Jones S.E.: Telangiectasia macularis eruptiva perstans: a case report and review of the literature. Clin Exp Dermatol 1998, 23, 38-39.
  9. Scherber R.M., Borate U.: How we diagnose and treat systemic mastocytosis in adults. Br J Haematol 2017, 180, 11-23.
  10. Valent P., Escribano L., Broesby-Olsen S., Hartmann K., Grattan C., Brockow K., et al.: Proposed diagnostic algorithm with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy 2014, 69, 1267-1274.
  11. Broesby-Olsen S., Dybedal I., Gülen T., Kristensen T.K., Møller M.B., Ackermann L., et al.: Multidisciplinary management of mastocytosis: Nordic expert group consensus. J Eur Acad Dermatol Venereol 2016, 96, 602-612.
  12. Bojahr K., Dylczyk-Sommer A., Biedrzycka A., Piskunowicz M., Lange M., Mital A., et al.: Preparation of patients with mastocytosis and mast cell activation syndrome for surgery, childbirth, and radiological examinations. Pol J Allergol 2023, 10, 301-309.
  13. Le M., Miedzybrodzki B., Olynch T., Chapdelaine H., Ben-Shoshan M.: Natural history and treatment of cutaneous and systemic mastocytosis. J Allergy Clin Immunol 2017, 129, 896-901.
  14. Watkins C.E., Bokor W.B., Leicht S., Youngberg G., Krishnaswamy G.: Telangiectasia macularis eruptiva perstans: More than skin deep. Case Rep Dermatol 2011, 3, e12.
  15. Valent P., Akin C., Metcalfe D.D.: Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. J Allergy Clin Immunol 2017, 129, 1420-1427.
  16. Czarny J.H., Lange M., Niedoszytko M.B., Kwiecińska B., Górska A., Ługowska-Umer H., et al.: Drug hypersensitivity reactions and allergy in patients with mastocytosis. Przegl Dermatol 2017, 104, 22-30.
  17. Mortimore A.M., Barsoum R., Lambie D., McMeniman E.: A case of omalizumab as a successful treatment for telangiectasia macularis eruptiva perstans. Australas J Dermatol 2022, 63, 102-104.
  18. Lee H., Li T., Wisell J., Schowinsky J., Robinson W.A.: Avapritinib for cutaneous mastocytosis. Acta Derm Venereol 2021, 101, adv00362.
  19. Vannorsdall E.J., Collins J.A., Chen Q.C., Sarai G., Baer M.R.: Symptomatic response to imatinib mesylate in cutaneous mastocytosis associated with chronic myelomonocytic leukemia. Leuk Lymphoma 2013, 20, 349-353.
  20. Panaszek B.: Plejotropowe działanie omalizumabu w chorobach alergicznych i niealergicznych. Alergologia.org.pl [online] 2017 [access: 10.09.2024]. http://alergia.org.pl/wp-content/uploads/2017/08/Plejotropowe-działanie-omalizumabu-w-chorobach-alergicznych-i-niealergicznych.pdf.
  21. Chia J.C., Mydlarski P.R.: Dermatologic uses of omalizumab. J Dermatolog Treat 2017, 28, 332-337.
  22. Gotlib J., Castells M., Elberink H.O., Siebenhaar F., Hartmann K., Broesby-Olsen S., et al.: Avapritinib versus placebo in indolent systemic mastocytosis. NEJM Evid 2023, 2, EVIDoa2200339.
  23. Veitch S., Radia D.H.: Recent advances in the therapeutic management of advanced systemic mastocytosis. Ther Adv Hematol 2023, 14, 80.
  24. Niedoszytko M.: Mastocytoza rozpoznanie i leczenie. Wydawnictwo Benkowski, Białystok, 2007, 15-124
Copyright: © 2026 Polish Dermatological Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Indeks osobowy
Udostępnij
without publication fees
without publication fees
Dostępne w
Zintergrowane z
plagiat pl
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications